Previous 10 | Next 10 |
2023-08-29 09:10:07 ET More on Celularity Celularity announces $3M registered direct offering, stock up 8% Seeking Alpha’s Quant Rating on Celularity Earnings data for Celularity For further details see: Celularity announces multi-year research col...
Celularity to provide research support for Regeneron's targeted, allogeneic, chimeric antigen receptor (CAR) T-cell therapy Agreement underscores Celularity's demonstrated expertise in cell therapy research FLORHAM PARK, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. ...
2023-07-27 10:37:00 ET Celularity ( NASDAQ: CELU ) on Thursday announced an ~$3M registered direct offering of class A shares and warrants. Shares +7.9% in morning trade. The firm inked a deal with a healthcare-focused institutional investor for the ...
FLORHAM PARK, N.J., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“ Celularity ”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced that it has entered into a definitive agreement with a ...
FLORHAM PARK, N.J. and TAMPA, Fla., July 27, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, and Verséa Ophthalmics, LLC (“Verséa Ophthal...
FLORHAM PARK, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity,” “the Company”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that it will present data on its...
FLORHAM PARK, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company will present data from a new product technology in developme...
Data published online in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor gene knockout (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower tissue factor (TF) expression, activity, and thrombotic effects, providing a feasible strategy potentially to improv...
2023-05-26 11:56:25 ET Summary Even with new management in place, it is unlikely that a company will regain market share or turn profitable after it has lost its way. Carolina Dybeck Happe joined General Electric Company in March 2020 at a time when revenue had been declining shar...
2023-05-23 08:17:51 ET Celularity ( NASDAQ: CELU ) has received a $45M purchase order for Celularity private label Halal-Certified biomaterial products from Jamjoom Medical Store. This marks the first purchase order received by Celularity under its recently announced expan...
News, Short Squeeze, Breakout and More Instantly...
For the first quarter 2024, Celularity expects combined net sales of $14.8 million for its advanced biomaterial product and biobanking businesses, compared to the $10.25 million to $11.5 million guidance range previously announced in February. Celularity’s expected com...
3D Systems Corporation (DDD) is expected to report $-0.11 for Q1 2024 ZW Data Action Technologies Inc. (CNET) is expected to report for Q1 2024 Celularity Inc. (CELU) is expected to report for Q1 2023 DMK Pharmaceuticals Corporation (DMKPQ) is expected to report for Q1 2024 Atlant...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...